TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00913198
Drug: IV CP-4126
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03893734
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
Study: NCT03893734
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
Study: NCT03420768
Drug: BMS-986263
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT00865631
Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT00865631
Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study: NCT02675959
Drug: Defibrotide
Normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
Study: NCT00006473
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02146976
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: introvenious infusion of propofol
Study: NCT02146976
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
Study: NCT00268892
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.
Study: NCT01017939
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
Study: NCT01017939
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
Study: NCT01017939
Drug: Dextromethorphan hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
Study: NCT01301924
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine.
Study: NCT02501551
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
Study: NCT00036647
Drug: Tarceva (erlotinib HCl, OSI-774 )
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03069677
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
Study: NCT00469053
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04659551
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
Study: NCT04659551
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg i.m. every 4 weeks until surgery
Study: NCT04659551
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25 mg oral continuous daily dose until surgery
Study: NCT04659551
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
Study: NCT00518882
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg once daily for s.c. (under the skin) injection.
Study: NCT00518882
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mcg twice daily for s.c. (under the skin) injection.
Study: NCT03395639
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
Study: NCT02288208
Drug: Birinapant
Normalized name: Birinapant
DrugBank: Birinapant (DB11782)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00919984
Drug: IP chemotherapy
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
Study: NCT00775528
Drug: Pancrelipase Delayed Release
Normalized name: Pancrelipase Delayed-Release Capsules
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000, 6,000 and 12,000 unit Lipase Capsules
Study: NCT04060511
Drug: HS-10342
Normalized name: sodium chloride 0.00342 MEQ/MG
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
Study: NCT02087176
Drug: pegfiligrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
Study: NCT02155374
Drug: Sliding scale insulin
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155374
Drug: Glucose lowering medication
Normalized name: biguanide blood glucose lower drugs
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular glucose lowering medication as prescribed by the patient's own physician before study entry
Study: NCT00006263
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006263
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02390648
Drug: Ginger
Normalized name: Ginger
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
Study: NCT03544814
Drug: icotinib combined with pemetrexed plus cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
Study: NCT03544814
Drug: first icotinib and then pemetrexed plus cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
Study: NCT01174524
Drug: gestoden 60 mcg
Normalized name: gestodene
DrugBank: Gestodene (DB06730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gestoden 60 mcg, once a day, administered in 24/4 regimen.
Study: NCT01174524
Drug: ethinylestradiol 15 mcg
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
Study: NCT00016276
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00016276
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00016276
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01709994
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/day of aspirin
Study: NCT01795248
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg liraglutide
Study: NCT00791141
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
Study: NCT02731963
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
Study: NCT01046578
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
Study: NCT01046578
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
Study: NCT01046578
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
Study: NCT01046578
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
Study: NCT01046578
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
Study: NCT00020267
Drug: interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020267
Drug: MAGE-12 peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020267
Drug: Montanide ISA-51
Normalized name: isopropyl alcohol
DrugBank: Incomplete Freund's adjuvant (DB17475)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01872702
Drug: malaria elimination using DP and low-dose primaquine
Normalized name: ethinyl estradiol
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
Study: NCT00641784
Drug: Magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Magnesium 6 gram load, 3 grams/hr
Study: NCT00641784
Drug: Nifedlipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
Study: NCT00606502
Drug: Pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
Study: NCT00606502
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
Study: NCT01615887
Drug: lisdexamfetamine sulfate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
Study: NCT01983514
Drug: 8IU intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01983514
Drug: 24 IU intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01983514
Drug: 1 IU intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01289951
Drug: Raltegravir 400 mg/12hours
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00258375
Drug: custirsen sodium
Normalized name: Custirsen
DrugBank: Custirsen (DB05487)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00258375
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01233843
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 70 mg per m2 and per day for four days. day 1; day 22; day 43
Study: NCT01059786
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Study: NCT01059786
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Study: NCT01001260
Drug: 325 mg ASA
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose of aspirin prior to PTCA
Study: NCT00759720
Drug: TAK-559 and glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
Study: NCT00759720
Drug: TAK-559 and glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
Study: NCT00759720
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
Study: NCT04698772
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
Study: NCT04698772
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
Study: NCT02211014
Drug: acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01059786
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
Study: NCT04130178
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous saline injection
Study: NCT02619448
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT01059786
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of infusion-related symptoms with diphenhydramine is recommended.
Study: NCT02619448
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy
Study: NCT01059786
Drug: Antihistamines
Normalized name: ANTIHISTAMINES
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Study: NCT01543555
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
Study: NCT00521989
Drug: CRx-102 (2.7/90)
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-102 dose 1
Study: NCT00521989
Drug: CRx-102 (2.7/180)
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-102 dose 2
Study: NCT00521989
Drug: CRx-102 (2.7/360)
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-102 dose 3
Study: NCT00005026
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005026
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005026
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00761449
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
Study: NCT02712801
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose will be adjusted according to the child's weight.
Study: NCT02712801
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose will be adjusted according to the child's weight.
Study: NCT02712801
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose will be adjusted according to the child's weight.
Study: NCT02712801
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose will be adjusted according to the child's weight.
Study: NCT00385788
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
Study: NCT00385788
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
Study: NCT00385788
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
Study: NCT00385788
Drug: Antithymocyte Globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant.